<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="decrease">
            <roleset id="decrease.01" name="make smaller&#x0A;" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing decrease&#x0A;" />
                    <role n="2" descr="location&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A 0 (loco marA) was decrease a reduction in porin expression OmpF in mutants of Escherichia coli resistant to multiple antibiotics (Mar).</text>
                    <arg n="1">porin expression OmpF</arg>
                    <arg n="2">resistant to multiple antibiotics (Mar)</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A 0 (melatonin treatment) was considered a reduction in the synthesis of lipodyl peroxide, and allowed the recovery of both decrease glutathione and scavenger enzyme.</text>
                </example>
                <example src="EGRAM" no="2">
                    <text>A0 has decreased lipid peroxide synthesis, and has enabled the recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>A0 has the ability to decrease nitric induction promoter of nirB without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="1">nitric induction promoter of nirB</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>A0 is able to decrease the nitric induction of nitric induction promoter of nirB, without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="1">nitric induction promoter of nirB</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>A0 is characterized by decreased nitric induction of nitric induction promoter of nirB, without decrease nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="1">nitric induction promoter of nirB</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>A0 is thought to decrease nitrite induction in nirB promoter, although it does not suppress nitrate induction, suggesting that a second nitrate response factor may occur.</text>
                    <arg n="1">nirB promoter</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>ArchA gene suppression causes a 2-fold increase in the expression ptsG, and excess of ArcA can significantly decrease the consumption of glucose.</text>
                    <arg n="0">excess of ArcA</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>ArchA gene suppression causes a 2-fold increase in the expression ptsG, and excess of ArcA is thought to have significantly decreased the consumption of glucose.</text>
                    <arg n="0">excess of ArcA</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>ArchA gene suppression causes a 2-fold increase in the expression ptsG, and excess of ArcA may have significantly decreased the consumption of glucose.</text>
                    <arg n="0">excess of ArcA</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>C51 microcin production has been shown to decrease or is absent in rpoS, crp and cyanol mutant cells.</text>
                    <arg n="1">C51 microcin production</arg>
                    <arg n="2">rpoS, crp and cyanol mutant cells</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>C51 microcin production was shown to decrease or be absent in rpoS, crp and cyanol mutant cells.</text>
                    <arg n="1">C51 microcin production</arg>
                    <arg n="2">rpoS, crp and cyanol mutant cells</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Clara cell secretor protein levels decrease in smokers NLF, and NLF smokers have also been found to decreased increased ratios of a truncated variant of lipocortin-1, three alpha acid forms (1)-antitrypsin, and a phosphorylated form of cyttin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                </example>
                <example src="EGRAM" no="13">
                    <text>Clara cell secretor protein levels decrease in smokers NLF, and it is also found that the NLF of smokers contains decreased ratios of a truncated variant of lipocortin-1, three alpha acid forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                </example>
                <example src="EGRAM" no="14">
                    <text>Clara cell secretor protein levels were shown to be decreased in smokers NLF, and it has also been found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cyttin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                </example>
                <example src="EGRAM" no="15">
                    <text>Clear cell secretory protein levels were decreased in the NLF of smokers, and it was also found that the NLF of smokers presented an increase in the ratio of a truncated lipocortin-1 variant, three alpha acid (1)-antitrypsin forms and a phosphorylated form of S.Syntrophin cyttine binds to a dystropine exon spalmate spac</text>
                </example>
                <example src="EGRAM" no="16">
                    <text>Clench cell secreting protein levels is considered to be decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S. Syntrophin binds to an alternative pulsed exon of</text>
                    <arg n="1">Clench cell secreting protein levels</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Clench cell secretory protein levels can be decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an alternative pulsed exon of</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Clench cell secretory protein levels can be decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of dystrophin alterna</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Clench cell secretory protein levels can be decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of dystrophin in</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Clench cell secretory protein levels is able to be decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Clench cell secretory protein levels is able to decreased the NLF of smokers, and it was also found that the NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of dys</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Clench cell secretory protein levels is considered to be decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of dy</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Clench cell secretory protein levels is decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of dystrophin alternative</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Clench cell secretory protein levels may be decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of dystrophin</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Clench cell secretory protein levels may have been decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of dy</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Clench cell secretory protein levels may have been decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an alternative pul</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Clench cell secretory protein levels was able to decreased the NLF of smokers, and it was also found that the NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an alternative pulsed</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Clench cell secretory protein levels was decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of dystrophin in</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Clench cell secretory protein levels was decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an alternative pulsed exon</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Clench cell secretory protein levels was decreased in the NLF of smokers, and it was also found that the NLF of smokers presented increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an exon of dystrophin</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Clench cell secretory protein levels would be decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an alternative pulsed exon</text>
                    <arg n="1">Clench cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Crystalline cell secreting protein levels could be decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an alternative pulsed exon</text>
                    <arg n="1">Crystalline cell secreting protein levels</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Crystalline cell secreting protein levels may be decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an alternative pulsed exon</text>
                    <arg n="1">Crystalline cell secreting protein levels</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Crystalline cell secreting protein levels will be decreased in NLF of smokers, and it has also been found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an alternative pulsed</text>
                    <arg n="1">Crystalline cell secreting protein levels</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Crystalline cell secretory protein levels could be decreased in NLF of smokers, and it was also found that NLF of smokers contained increased proportions of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cystatin S.Syntrophin binds to an alternative pulsed exon</text>
                    <arg n="1">Crystalline cell secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Druption of narL could decrease nitrite induction of the nirB promoter without suppressing nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">Druption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Druption of narL decreased digit induction of the nirB promoter without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">Druption of narL</arg>
                    <arg n="1">digit induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Druption of narL has decreased digit induction of the nirB promoter without suppressing nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">Druption of narL</arg>
                    <arg n="1">digit induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Druption of narL has the ability to decrease nitrite induction of the nirB promoter without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">Druption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Druption of narL is shown to decrease nitrite induction of the nirB promoter without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">Druption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Druption of narL may have decreased digit induction of the nirB promoter without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">Druption of narL</arg>
                    <arg n="1">digit induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Druption of narL was able to decrease nitrite induction of the nirB promoter without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">Druption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>Druption of narL will decrease digit induction of the nirB promoter without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">Druption of narL</arg>
                    <arg n="1">digit induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>Elevation of the arcA gene caused a 2-fold increase in ptsG expression, and it was observed that expression of ArcA overexpression significantly decreased glucose exposure.</text>
                    <arg n="0">expression of ArcA overexpression</arg>
                    <arg n="1">glucose exposure</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Elevation of the arcA gene causes a 2-fold increase in ptsG expression, and A0 is able to significantly decrease glucose intake.</text>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Elevation of the arcA gene causes a 2-fold increase in ptsG expression, and excessive arcA expression has been shown to significantly decrease glucose intake.</text>
                    <arg n="0">excessive arcA expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Elevation of the arcA gene causes a 2-fold increase in ptsG expression, and glucose intake will be significantly decreased to excessive ArcA expression will be significantly decreased.</text>
                    <arg n="0">excessive ArcA expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Elevation of the arcA gene causes a 2-fold increase in ptsG expression, and glucose intake would be significantly decreased by excessive ArcA expression would be significantly decreased.</text>
                    <arg n="0">excessive ArcA expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Elevation of the arcA gene causes a 2-fold increase in ptsG expression, and it has been shown that glucose intake was significantly decreased to excessive ArcA expression.</text>
                    <arg n="0">excessive ArcA expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Expressive porin expression OmpF in multi-antibiotic resistant mutants (Mar) of Escherichia coli is shown to be decreased by marA place.</text>
                    <arg n="0">marA place</arg>
                    <arg n="1">Expressive porin expression OmpF</arg>
                    <arg n="2">multi-antibiotic resistant mutants (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Expressive porin expression OmpF in multi-antibiotic resistant mutants (Mar) of Escherichia coli may have been decreased by mara place.</text>
                    <arg n="0">mara place</arg>
                    <arg n="1">Expressive porin expression OmpF</arg>
                    <arg n="2">multi-antibiotic resistant mutants (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>If this 30 amino acid distance is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection can be decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>If this 30 amino acid distance is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection can be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>If this 30 amino acid distance is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection could be decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>If this 30 amino acid distance is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection is shown to be decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>If this 30 amino acid distance is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection is thought to be decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>If this 30 amino acid distance is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection is thought to have been decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>If this 30 amino acid distance is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA would be severely affected and protection would be decreased, or even suppressed in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeast#1 and in the AsnRS chimera of yeast#2 (Figure 5B), the tRNA binding is strongly affected and protection may have been decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeast#1 and in the AsnRS chimera of yeast#2 (Figure 5B), the tRNA binding is strongly affected and protection will be decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), tRNA binding is strongly affected and protection has been decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), tRNA binding is strongly affected and protection may be decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection has been considered decreased or even abolished in the case of the human AspRS chimera#1 (Ta</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection has been decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection is able to be decreased or even abolished in the case of the human AspRS chimera#1 (Table</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection is believed to be decreased or even abolished in the case of the human AspRS chimera#1 (</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection may be decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection was able to be decreased or even abolished in the case of the human AspRS chimera#1 (Ta</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection will be decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection would be decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (picture 5B), the tRNA binding is strongly affected and protection may be decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>If this 30-amino acid distance is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (picture 5B), the tRNA binding is strongly affected and protection may have been decreased or even abolished in the case of the human AspRS chimera#1 (Ta</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>If this distance of 30 amino acids is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection has been decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>If this distance of 30 amino acids is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection is capable of decreased, or even abolishing in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>If this distance of 30 amino acids is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection may have been decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>If this distance of 30 amino acids is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection may have been decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>If this distance of 30 amino acids is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA is strongly affected and protection was able to decreased, or even abolish in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>If this distance of 30 amino acids is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA was strongly affected and it was shown that protection was decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>If this distance of 30 amino acids is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA was strongly affected and protection was decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>If this distance of 30 amino acids is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA will be severely affected and protection will be decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>If this distance of 30 amino acids is not maintained, as in AspRS chimera#1, or in the yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), binding to the tRNA will be severely affected and protection will have been decreased, or even abolished in the case of AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>If this distance of 30 amino acids is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection has been decreased or even abolished in the case of the human AspRS chimera#1 (Table</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>If this distance of 30 amino acids is not maintained, such as in the human AspRS chimera#1, or in the LysTS chimera of yeasts#1 and in the AsnRS chimera of yeasts#2 (Figure 5B), the tRNA binding is strongly affected and protection is decreased or even abolished in the case of the human AspRS chimera#1 (Table).</text>
                    <arg n="1">protection</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>In brain areas of patients with schizophrenia that are homologous to those of non-psychiatric subjects, RNAM content was able to decreased significantly (4050%; see Table 2).</text>
                    <arg n="0">RNAM content</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>In brain areas of patients with schizophrenia that are homologous to those of non-psychiatric subjects, RNLN mRNA content decreased a significant decrease (4050%; see Table 2).</text>
                    <arg n="0">RNLN mRNA content</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>In brain areas of patients with schizophrenia that are homologous to those of non-psychiatric subjects, RNLN mRNA content is able to decreased significantly (4050%; see Table 2).</text>
                    <arg n="0">RNLN mRNA content</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>In brain areas of patients with schizophrenia that are homologous to those of non-psychiatric subjects, the contents of MRNA may have decreased significantly (4050%; see Table 2).</text>
                </example>
                <example src="EGRAM" no="88">
                    <text>In brain areas of patients with schizophrenia that are homologous to those of non-psychiatric subjects, the contents of RNA mRNA can decreased significantly (4050%; see Table 2).</text>
                </example>
                <example src="EGRAM" no="89">
                    <text>In brain areas of patients with schizophrenia who are homologous to those of non-psychiatric subjects, RELN mRNA content is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>In brain areas of patients with schizophrenia who are homologous to those of non-psychiatric subjects, RELN mRNA content may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>In brain areas of patients with schizophrenia who are homologous to those of non-psychiatric subjects, RELN mRNA content may have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>In brain areas of patients with schizophrenia who are homologous to those of non-psychiatric subjects, RELN mRNA content was able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>In brain decreasingas of patients with schizophrenia that decreasing homologous to those of non-psychiatric subjects, RNAM content was significantly lower (4050%; see Table 2).</text>
                    <arg n="0">RNAM content</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>In brain decreasingas of patients with schizophrenia who decreasing homologous to those of non-psychiatric subjects, RELN mRNA content was significantly lower (4050%; see Table 2).</text>
                    <arg n="0">RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consisting of these levels of expression the methionine content is lowered and decreased), and neither RAP2 nor RAP3 is coimmunoprecipity in the RAP1 mutants.</text>
                </example>
                <example src="EGRAM" no="96">
                    <text>In contrast, only low levels of truncated RAP1 peptides (consisting of reduced expression levels and decreased methionine content) would be detected, and neither RAP2 nor RAP3 would be coimmunoprecipitated in RAP1 mutants.</text>
                </example>
                <example src="EGRAM" no="97">
                    <text>In contrast, only low levels of truncated RAP1 peptides are detected (consistent with this expression level may have been reduced and methionine content may have been decreased), and neither RAP2 nor RAP3 are co-immunoprecipitate in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>In contrast, only low levels of truncated RAP1 peptides are detected (consistent with this expression may be lower and methionine content may be decreased), and neither RAP2 nor RAP3 are co-immunoprecipitate in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>In contrast, only low levels of truncated RAP1 peptides are detected (consisting of these expression levels can be decreased and metonic content can be decreased), and neither RAP2 nor RAP3 are coimmunoprecipites in RAP1 mutants.</text>
                    <arg n="1">metonic content</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>In contrast, only low levels of truncated RAP1 peptides are detected (consisting of these expression levels can be reduced and the methionine content can be decreased), and neither RAP2 nor RAP3 are coimmunoprecipites in RAP1 mutants.</text>
                </example>
                <example src="EGRAM" no="101">
                    <text>In contrast, only low levels of truncated RAP1 peptides are detected (consisting of these expression levels may have been lower and methionine content may have been decreased), and neither RAP2 nor RAP3 are co-immunoprecipitations in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>In contrast, only low levels of truncated RAP1 peptides are detected (consisting of this level of expression may have been decreased and methionine content may have been decreased), and neither RAP2 nor RAP3 are coimmunoprecipities in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>In contrast, only low levels of truncated RAP1 peptides have been detected (consisting of these expression levels have been decreased and methionine content has been decreased), and neither RAP2 nor RAP3 have been coimmunoprecipitated in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>In contrast, only low levels of truncated RAP1 peptides were decreased (consisting of this expression, A1 levels (methionine content) were lower and there was no coimmunoprecipitation of RAP2 and RAP3 in RAP1 mutants.</text>
                </example>
                <example src="EGRAM" no="105">
                    <text>In contrast, only low levels of truncated RAP1 peptides were detected (consisting of these expression levels could be reduced and methionine content could be decreased), and neither RAP2 nor RAP3 were coimmunoprecipitated in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>In contrast, only low levels of truncated RAP1 peptides were detected (consisting of these levels of expression could be reduced and methionine content could be decreased), and neither RAP2 nor RAP3 were coimmunoprecipitated in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>In contrast, only low levels of truncated RAP1 peptides were detected (expression levels were lower and methionine content was decreased), and neither RAP2 nor RAP3 were coimmunoprecipities in RAP1 mutants.</text>
                </example>
                <example src="EGRAM" no="108">
                    <text>In contrast, only low levels of truncated RAP1 peptides will be detected (consisting of these expression levels will be reduced and methionine content decreased), and neither RAP2 nor RAP3 will be coimmunoprecipitated in RAP1 mutants.</text>
                </example>
                <example src="EGRAM" no="109">
                    <text>In contrast, only low levels of truncated RAP1 peptides will be detected (which match this level of expression will have been decreased and methionine content will have been decreased), and neither RAP2 nor RAP3 will be coimmunoprecipitated in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>In contrast, only the low levels of truncated RAP1 peptides are detected (consistent with this expression is able to be lowered and teor methionine is able to be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitate in RAP1 mutants.</text>
                    <arg n="1">teor methionine</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>In contrast, only the low levels of truncated RAP1 peptides are detected (consistent with this expression may be lower and methionine content may be decreased), and neither RAP2 nor RAP3 are co-immunoprecipitate in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>In contrast, only the low levels of truncated RAP1 peptides are detected (consistent with this expression may have been lower and methionine content may have been decreased), and neither RAP2 nor RAP3 co-immunoprecipitate in RAP1 mutants are co-immunoprecipitate.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>In contrast, only the low levels of truncated RAP1 peptides are detected (consistent with this expression, the levels are decreased and methionine content is decreased), and neither RAP2 nor RAP3 are co-immunoprecipitate in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>In contrast, only the low levels of truncated RAP1 peptides were decreased (consistent with this expression, A1 levels (methionine content) were lower and there was no co-immunoprecipitation of RAP2 and RAP3 in RAP1 mutants.</text>
                </example>
                <example src="EGRAM" no="115">
                    <text>In contrast, only the low levels of truncated RAP1 peptides were detected (consistent with these expression levels would be decreased and methionine content would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitate in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>In contrast, only the low levels of truncated RAP1 peptides were detected (consistent with this expression it was possible to decreased and methionine content was able to decreased, and neither RAP2 nor RAP3 was co-immunoprecipitate in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>In contrast, only the low levels of truncated RAP1 peptides were detected (consistent with this expression it was possible to decreased and methionine content was able to decreased, and neither RAP2 nor RAP3 was coimmunoprecipity in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>In contrast, only the low levels of truncated RAP1 peptides were detected (consistent with this expression, the levels may be decreased and methionine content may be decreased), and neither RAP2 nor RAP3 were co-immunoprecipitate in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>In contrast, only the low levels of truncated RAP1 peptides were detected (consisting of these expression levels could be reduced and methionine content could be decreased), and neither RAP2 nor RAP3 were coimmunoprecipites in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>In contrast, only the low levels of truncated RAP1 peptides will be decreased (consisting of these expression levels, there will be a reduction in methionine content), and neither RAP2 nor RAP3 will be coimmunoprecipitate in RAP1 mutants.</text>
                </example>
                <example src="EGRAM" no="121">
                    <text>In contrast, only the low levels of truncated RAP1 peptides will be detected (consistent with this expression level) and methionine content have been decreased, and neither RAP2 nor RAP3 will be co-immunoprecipitate in RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>In patients with schizophrenia that are homologous to non-psychiatric subjects, the contents of RNA mRNA will be significantly decreased (4050%; see Table 2).</text>
                </example>
                <example src="EGRAM" no="123">
                    <text>In schizophrenia patients who are homologous to non-psychiatric mRNAs, the content of RELN decreased significantly (4050%; see Table 2).</text>
                </example>
                <example src="EGRAM" no="124">
                    <text>In schizophrenia patients who are homologous to non-psychiatric mRNAs, the content of RELN mRNA is decreasing significantly (4050%; see Table 2).</text>
                </example>
                <example src="EGRAM" no="125">
                    <text>In schizophrenia patients who are homologous to non-psychiatrics, the contents of MRNA were significantly decreased (4050%; see Table 2).</text>
                </example>
                <example src="EGRAM" no="126">
                    <text>In schizophrenia patients who are homologous to those of non-psychiatric subjects, the contents of MRNA reLN may have decreased significantly (4050%; see Table 2).</text>
                </example>
                <example src="EGRAM" no="127">
                    <text>In schizophrenia patients who are homologous to those of non-psychiatric subjects, the contents of RNA mRNA can decreased significantly (4050%; see Table 2).</text>
                </example>
                <example src="EGRAM" no="128">
                    <text>In schizophrenia patients who are homologous to those of non-psychiatric subjects, the contents of RNA mRNA would be significantly decreased (4050%; see Table 2).</text>
                </example>
                <example src="EGRAM" no="129">
                    <text>In the brain areas of patients with schizophrenia homologous to those of non-psychiatric individuals, it is demonstrated that MRNA RELN content is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">MRNA RELN content</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>In the brain areas of patients with schizophrenia homologous to those of non-psychiatric subjects, mRNA reLN content is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">mRNA reLN content</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>In the brain areas of patients with schizophrenia homologous to those of non-psychiatric subjects, mRNA reLN content may decreased significantly (4050%; see Table 2).</text>
                    <arg n="0">mRNA reLN content</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>In the brain areas of patients with schizophrenia who are homologous to those of non-psychiatric subjects, mRNA reLN content is decreased a significant reduction (4050%; see Table 2).</text>
                    <arg n="0">mRNA reLN content</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>In the brain areas of patients with schizophrenia who are homologous to those of non-psychiatric subjects, mRNA reLN content will be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">mRNA reLN content</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>In the brain areas of patients with schizophrenia who are homologous to those of non-psychiatric subjects, mRNA reLN content would have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">mRNA reLN content</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>In the cerebral areas of patients of schizophrenia homologous to non-psychiatric subjects, the contents of MRNA reLN can decreased significantly (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA reLN</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>In the cerebral areas of schizophrenia patients homologous to non-psychiatric subjects, the contents of MRNA RELN is significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA RELN</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, RNLN mRNA content was believed to decreased significantly (4050%; see Table 2).</text>
                    <arg n="0">RNLN mRNA content</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, it is shown that the contents of MRNA RELN is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA RELN</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, it was shown that the contents of MRNA was significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, the contents of MRNA can be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, the contents of MRNA reLN has decreased significantly (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA reLN</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, the contents of MRNA reLN is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA reLN</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, the contents of MRNA reLN is thought to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA reLN</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, the contents of MRNA reLN may have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA reLN</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, the contents of MRNA reLN will have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the contents of MRNA reLN</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>In the cerebral areas of schizophrenia patients homologous to those of non-psychiatric subjects, the reLN mRNA content would be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the reLN mRNA content</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>It is believed that natron activation decreases nirB nitrite promoter induction without suppressing nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">natron activation</arg>
                    <arg n="1">nirB nitrite promoter induction</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>It is believed that the production of C51 microcin decreases or is absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>It is thought that the levels of secreting proteins of the Clear Cells have been reduced in the NLF of smokers, and NLF smokers also contain an decreased ratio of a truncated lipocortin-1 variant, three forms of alpha (1)-antitrypsin and a phosphorylated form of S. Syntrophin cyttine binds to an inhaled exon of dystropine.</text>
                </example>
                <example src="EGRAM" no="150">
                    <text>It was believed that narL drive decreases nirB promoter nitrite induction without suppressing nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>It was believed that the nitrite induction of the nirB promoter was decreased by narL drive that did not suppress nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>It was shown that lipid peroxide synthesis was decreased by Tractament with melatonin, and allowed for the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractament with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>It was shown that the narL drive decreases the nirB promoter nitrite induction without suppressing nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Local MEF2 binding sites have been reported in several cardiac promoters and mutation decreases the promotion activity in cardiomiocytics.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promotion activity</arg>
                    <arg n="2">cardiomiocytics</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Local MEF2 binding sites have been reported in various cardiac promoters and mutation would decrease promotion activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promotion activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Local binding sites of MEF2 have been reported in several cardiac promoters and its mutation decreases promoter activity in cardiomyocytes.</text>
                    <arg n="0">its mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Local binding sites of MEF2 have been reported in several cardiac promoters and mutation would decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Loco de Abraa is thought to decrease the expression of OmpF porin in multi-antibiotic (Mar) resistance mutants of Escherichia coli.</text>
                    <arg n="0">Loco de Abraa</arg>
                    <arg n="1">OmpF porin</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Loco de MarA decreased the expression of opmF porin expression in A2 mutants (multiresistant antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">Loco de MarA</arg>
                    <arg n="1">opmF porin expression</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Loco de MarA has been shown to decrease the expression of opmF porin expression in A2 mutants (multiresistant antibiotic (Mar) of Escherichia coli.</text>
                    <arg n="0">Loco de MarA</arg>
                    <arg n="1">opmF porin expression</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Loco de MarA has the ability to decrease the expression of OmpF porin in A2 mutants (Resistance to Multi-antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">Loco de MarA</arg>
                    <arg n="1">OmpF porin</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Loco de MarA may decrease the expression of OmpF porin expression in multi-antibiotic (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">Loco de MarA</arg>
                    <arg n="1">OmpF porin expression</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Loco de MarA may decrease the expression of opmF porin expression in A2 mutants (multiresistant antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">Loco de MarA</arg>
                    <arg n="1">opmF porin expression</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Loco de MarA was able to decrease the expression of opmpF porin expression in A2 mutants (multiresistant antibiotic (Mar) of Escherichia coli.</text>
                    <arg n="0">Loco de MarA</arg>
                    <arg n="1">opmpF porin expression</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Loco de MarA would have decreased the expression of or OmpF porin in A2 mutants (multiresistant antibiotic (Mar) of Escherichia coli.</text>
                    <arg n="0">Loco de MarA</arg>
                    <arg n="1">or OmpF porin</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and its mutation had the ability to decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">its mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and its mutation may decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">its mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and its mutation will decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">its mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and mutation decreased promoting activity in cardiomiocytics.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomiocytics</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and mutation decreased promoting activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and mutation has been able to decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and mutation has the ability to decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and mutation is able to decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and mutation may decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and promoting activity can be decreased in mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and promoting activity has been considered to be decreased by mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and promoting activity was decreased in mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>MEF2 binding sites have been reported in several cardiac promoters and six mutations has been considered to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>MEF2 binding sites have been reported in various cardiac promoters and promoter activity has been considered to be decreased by mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>MEF2 binding sites have been reported in various cardiac promoters and promoter activity is able to be decreased in mutation into cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>MEF2 binding sites have been reported in various cardiac promoters and promoter activity is believed to be decreased in mutation into cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>Mar location is demonstrated by decreasing the expression of OmpF porin expression in Mar mutants of Escherichia coli.</text>
                    <arg n="0">Mar location</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">Mar</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>MarA locus would have decreased the or OmpF porin expression in A2 mutants (multi-resistant antibiotics (Mar) of Escherichia coli).</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">or OmpF porin expression</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>MarA site decreases the expression of OmpF porin in A2 mutants (multiresistant antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">MarA site</arg>
                    <arg n="1">OmpF porin</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>MarA site may have decreased the expression of OmpF porin expression in A2 mutants (Schirichia coli resistant mutant mutant mutant mutants).</text>
                    <arg n="0">MarA site</arg>
                    <arg n="1">OmpF porin expression</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and its mutation had the ability to decrease promotion activity in cardiomiocytes.</text>
                    <arg n="0">its mutation</arg>
                    <arg n="1">promotion activity</arg>
                    <arg n="2">cardiomiocytes</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and mutation can decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and mutation is able to decrease promoting activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and mutation will decrease promotive activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promotive activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and promoting activity can be decreased by mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and promoting activity can be decreased by mutation in coriomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">coriomyocytes</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and promoting activity could be decreased by mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and promoting activity could be decreased by mutation in coriomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">coriomyocytes</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and promoting activity is decreased by mutation in coriomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">coriomyocytes</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and promoting activity is thought to be decreased by mutation in coriomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">coriomyocytes</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and promoting activity was able to be decreased by mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and promoting activity will be decreased by mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and promotive activity has decreased by mutation in cardiomycocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promotive activity</arg>
                    <arg n="2">cardiomycocytes</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and their mutation is thought to decrease promotive activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promotive activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>MeF2 binding sites have been reported in several cardiac promoters and whether its mutation is supposed to decrease promoter activity (cardiomyocytes).</text>
                    <arg n="0">whether its mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>MeF2 binding sites have been reported in several cardiac promoters, and mutation has the ability to decrease promotive activity in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promotive activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and mutation may decrease promotion activity in cardiomiocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promotion activity</arg>
                    <arg n="2">cardiomiocytes</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and promoter activity has been decreased by mutation to cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and promoter activity is able to decreased to mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and promoter activity may be decreased by mutation to cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and promoter activity was able to be decreased by mutation into cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and promoter activity will be decreased by mutation to cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and promoter activity would be decreased by mutation to cardiomycocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomycocytes</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and promoting activity is decreased in mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and promoting activity would be decreased in mutation in cardiomyocytes.</text>
                    <arg n="0">mutation</arg>
                    <arg n="1">promoting activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>MeF2 binding sites have been reported in various cardiac promoters and six mutations has been considered to decrease promotion activity in cardiomiocytes.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">promotion activity</arg>
                    <arg n="2">cardiomiocytes</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>Melatonin treatment is able to decrease lipodyl peroxide synthesis, and allows the recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="0">Melatonin treatment</arg>
                    <arg n="1">lipodyl peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>Melatonin treatment is able to decrease lipodyl peroxide synthesis, and allows the recovery of both reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">Melatonin treatment</arg>
                    <arg n="1">lipodyl peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>Melatonin treatment was able to decrease lipodyl peroxide synthesis, and allowed the recovery of both reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">Melatonin treatment</arg>
                    <arg n="1">lipodyl peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>Melatonin treatment will decrease lipodyl peroxide synthesis and allow for the recovery of both reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">Melatonin treatment</arg>
                    <arg n="1">lipodyl peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>NirB propulsion nitrite induction is thought to be decreased in narcotic induction, which is not suppressed by nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narcotic induction</arg>
                    <arg n="1">NirB propulsion nitrite induction</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>OmpF pore expression in A2 mutants (resistant to multiple antibiotics (Mar) of Escherichia coli) was considered decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">OmpF pore expression</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>OmpF porin expression in Many antibiotic resistant mutants (Mar) of Eschherichia coli can be decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">Many antibiotic resistant mutants (Mar) of Eschherichia coli</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>OmpF porin expression in multi-antibiotic resistant (Mar) mutants of Escherichia coli may have been decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multi-antibiotic resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>OmpF porin expression in multi-antibiotic resistant (Mar) mutants of Escherichia coli was thought to be decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multi-antibiotic resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>OmpF porin expression in multi-antibiotic resistant (Mar) mutants of Escherichia coli would be decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multi-antibiotic resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>OmpF porin expression in multi-antibiotic resistant (Mar) mutants of Eschrichia coli was able to be decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multi-antibiotic resistant (Mar) mutants of Eschrichia coli</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>OmpF porin expression in multi-antibiotic resistant mutants (Mar) of Escherichia coli will have decreased for MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multi-antibiotic resistant mutants (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>OmpF porin expression in multibiotic resistant mutants (Mar) of Escherichia coli could be decreased by mara place.</text>
                    <arg n="0">mara place</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multibiotic resistant mutants (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>Porin OmpF expression in multi-antibiotic resistant Escherichia coli (Mar) mutants are considered to be decreased by A0 (sea) (multi-antibiotic resistant Escherichia coli (Mar) mutants are considered to be decreased by sea.</text>
                    <arg n="0">sea</arg>
                    <arg n="1">Porin OmpF expression</arg>
                    <arg n="2">multi-antibiotic resistant Escherichia coli (Mar) mutants are considered to be decreased by A0 (sea)</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>Porina OmpF expression in multi-antibiotic resistant Escherichia coli (Mar) mutants can be decreased by A0 (sea) (multi-antibiotic resistant Escherichia coli (Mar) mutants can be decreased by sea.</text>
                    <arg n="0">sea</arg>
                    <arg n="1">Porina OmpF expression</arg>
                    <arg n="2">multi-antibiotic resistant Escherichia coli (Mar) mutants can be decreased by A0 (sea)</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>The A0 decreased the nitric induction of nitric induction promoter of nirB, although it did not suppress the induction of nitrates, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="1">nitric induction promoter of nirB</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>The A0 decreased the nitric induction promoter of the nirB while it did not suppress the induction of nitrate, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="1">nitric induction promoter of the nirB</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>The A1 level ( Clara cell secretor protein levels) was decreased in NLF smokers, and it was also found that the NLF smokers contained increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                </example>
                <example src="EGRAM" no="230">
                    <text>The NirB promoter nitrite induction is thought to be decreased by the narL drive that does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">NirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>The NirB promoter nitrite induction was able to be decreased by narc removal, which did not suppress nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narc removal</arg>
                    <arg n="1">NirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>The NirB promoter nitrite induction was decreased in the narc removal, which did not suppress nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narc removal</arg>
                    <arg n="1">NirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>The OmpF porin expression in multi-antibiotic resistant mutants (Mar) of Escherichia coli has been decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multi-antibiotic resistant mutants (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>The OmpF porin expression in multi-antibiotic resistant mutants (Mar) of Escherichia coli was decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multi-antibiotic resistant mutants (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>The clac secretor protein levels has been decreased in smokers NLF, and the NLF of smokers has also been found to contain increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">clac secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>The clean cell secretor protein levels will be decreased in the NLF of smokers, and the NLF of smokers has also been found to contain increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of the cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">clean cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>The clean cell secretor protein levels would be decreased in NLF smokers, and the NLF smokers have also been found to contain increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cyttin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">clean cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>The clench cell secretor protein levels is decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin and a phosphorylated form of cytotin S.Syntrophin binds to an alternative dystrophin exon.</text>
                    <arg n="1">clench cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>The clench cell secretor protein levels may have been decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three alpha acid forms (1)-antitrypsin and a phosphorylated form of cyttin S.Syntrophin binds to an alternative pultic</text>
                    <arg n="1">clench cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>The clench cell secretor protein levels was decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three alpha acid forms (1)-antitrypsin and a phosphorylated form of cyttin S.Syntrophin binds to an exon of dystrophin</text>
                    <arg n="1">clench cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>The clench cell secretor protein levels would be decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three alpha acid forms (1)-antitrypsin and a phosphorylated form of cyttin S.Syntrophin binds to an alternative pulsed exon</text>
                    <arg n="1">clench cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>The cloth cell secretor protein levels could be decreased in NLF smokers, and it was also found that the NLF smokers contained increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">cloth cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>The cloth cell secretor protein levels could be decreased in NLF smokers, and it was also found that the NLF smokers contained increased ratios of a truncated variant of lipocortin-1, three alpha acid forms (1)-antitrypsin, and a phosphorylated form of the cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">cloth cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>The cloth cell secretor protein levels could be decreased in NLF smokers, and the NLF smokers have also been found to contain increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">cloth cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>The cloth cell secretor protein levels may have been decreased in the NLF of smokers, and the NLF of smokers has also been found to contain increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">cloth cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>The cloth cell secretor protein levels was able to be decreased in the NLF of smokers, and the NLF of smokers has also been found to contain increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">cloth cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>The consisting protein levels of crystalline cells was decreased in NSF smoking, and it was also found that the NSF of smokers contained increased ratios of a truncated variant of lipocortin-1, three alpha acid forms (1)-antitrypsin and a phosphorylated cyttin S.Syntrophin binds to an alternative pulsed exon of distropin</text>
                    <arg n="1">consisting protein levels of crystalline cells</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>The consisting protein levels of crystalline cells would be decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin and a phosphorylated form of cytotin S.Syntrophin binds to an alternative ex-pulsate.</text>
                    <arg n="1">consisting protein levels of crystalline cells</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>The deletion of the arcA gene caused a 2-fold increase in the expression of ptsG, and it is observed that excessive expression of arcA significantly decreased glucose intake.</text>
                    <arg n="0">excessive expression of arcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>The deletion of the arcA gene caused a 2-fold increase in the expression ptsG, and it is observed that excessive arcA expression significantly decreased the consumption of glucose.</text>
                    <arg n="0">excessive arcA expression</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>The deletion of the arcA gene caused a 2-fold increase in the expression ptsG, and it was observed that the expression of ArcAs overexpression significantly decreased the consumption of glucose.</text>
                    <arg n="0">the expression of ArcAs overexpression</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>The deletion of the arcA gene causes a 2-fold increase in ptsG expression, and glucose intake is able to be significantly decreased to excessive Ark expression to make it significant.</text>
                    <arg n="0">excessive Ark expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>The deletion of the arcA gene causes a 2-fold increase in ptsG expression, and glucose intake was able to be significantly decreased in excessive ArcA expression will be significantly greater.</text>
                    <arg n="0">excessive ArcA expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>The deletion of the arcA gene causes a 2-fold increase in ptsG expression, and it is observed that excess ArcA significantly decreases glucose intake.</text>
                    <arg n="0">excess ArcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression of ptsG, and glucose intake is significantly decreased to excessive ArcA expression.</text>
                    <arg n="0">excessive ArcA expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression of ptsG, and overexpression of ArcA is shown to decreased significantly glucose intake.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and A0 is capable of significantly decreasing the consumption of glucose.</text>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and arcA expression can significantly decrease glucose consumption.</text>
                    <arg n="0">arcA expression</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and arcA expression could significantly decrease the consumption of glucose.</text>
                    <arg n="0">arcA expression</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and arcA expression is shown to significantly decrease the consumption of glucose.</text>
                    <arg n="0">arcA expression</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="261">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and arcA expression will significantly decrease the consumption of glucose.</text>
                    <arg n="0">arcA expression</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and arcA expression would significantly decrease the consumption of glucose.</text>
                    <arg n="0">arcA expression</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="263">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and excess of ArcA can significantly decrease the consumption of glucose.</text>
                    <arg n="0">excess of ArcA</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="264">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and excess of ArcA decreases significantly the consumption of glucose.</text>
                    <arg n="0">excess of ArcA</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="265">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and excess of ArcA expression is thought to significantly decrease the consumption of glucose.</text>
                    <arg n="0">excess of ArcA expression</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="266">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and excessive ArcA was able to significantly decrease the consumption of glucose.</text>
                    <arg n="0">excessive ArcA</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="267">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and it is observed that excess of ArcA significantly decreases the consumption of glucose.</text>
                    <arg n="0">excess of ArcA</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="268">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and it is thought that arcA expression significantly decreases the consumption of glucose.</text>
                    <arg n="0">arcA expression</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="269">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and it was shown that excessive arcA expression significantly decreases the consumption of glucose.</text>
                    <arg n="0">excessive arcA expression</arg>
                    <arg n="1">the consumption of glucose</arg>
                </example>
                <example src="EGRAM" no="270">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and it was shown that the glucose consumption was significantly decreased for the excessive expression of ArcA significantly.</text>
                    <arg n="0">the excessive expression of ArcA</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="271">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption can be significantly decreased by the excessive expression of ArcA significantly.</text>
                    <arg n="0">the excessive expression of ArcA</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="272">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption can be significantly decreased for the excessive expression of Arca to do so significantly.</text>
                    <arg n="0">the excessive expression of Arca</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="273">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption could be significantly decreased by the excessive expression of Arca significantly.</text>
                    <arg n="0">the excessive expression of Arca</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="274">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption has been significantly decreased for the excessive expression of Arca has been significantly decreased.</text>
                    <arg n="0">the excessive expression of Arca</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="275">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption is capable of being significantly decreased for the excessive expression of Arca to make it significantly.</text>
                    <arg n="0">the excessive expression of Arca</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="276">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption is shown to be significantly decreased for the excessive expression of ArcA significantly.</text>
                    <arg n="0">the excessive expression of ArcA</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="277">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption is significantly decreased by the excessive expression of arcA is significantly decreased.</text>
                    <arg n="0">the excessive expression of arcA</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="278">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption is thought to be significantly decreased by the excessive expression of ArcA significantly.</text>
                    <arg n="0">the excessive expression of ArcA</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="279">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption is thought to have been significantly decreased by the excessive expression of Arca to do so significantly.</text>
                    <arg n="0">the excessive expression of Arca</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="280">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption may have been decreased significantly for the excessive expression of ArcA significantly.</text>
                    <arg n="0">the excessive expression of ArcA</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="281">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption may have been significantly decreased by the excessive expression of Arca in a significant manner.</text>
                    <arg n="0">the excessive expression of Arca</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="282">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption was able to be significantly decreased for the excessive expression of Arca to do so significantly.</text>
                    <arg n="0">the excessive expression of Arca</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="283">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption will be significantly decreased for the excessive expression of ArcA will be significantly decreased.</text>
                    <arg n="0">the excessive expression of ArcA</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="284">
                    <text>The deletion of the arcA gene causes a 2-fold increase in the expression ptsG, and the glucose consumption would be significantly decreased by the excessive expression of ArcA significantly.</text>
                    <arg n="0">the excessive expression of ArcA</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="285">
                    <text>The deletion of the arcA gene has caused a 2-fold increase in the expression ptsG, and arcA expression has significantly decreased glucose consumption.</text>
                    <arg n="0">arcA expression</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="286">
                    <text>The discontinuation of nirB-promoter nitrite induction, although it does not decrease the induction of nitrate, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">nirB-promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="287">
                    <text>The elevation of the arcA gene caused approximately a 2-fold increase in the expression ptsG, and glucose intake decreased significantly in exposing excessive arcA will be significant.</text>
                    <arg n="0">exposing excessive arcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="288">
                    <text>The elevation of the arcA gene caused approximately a 2-fold increase in the expression ptsG, and glucose intake was significantly decreased by excessive expression ArcA will be significantly smaller.</text>
                    <arg n="0">excessive expression ArcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="289">
                    <text>The elevation of the arcA gene caused approximately a 2-fold increase in the expression ptsG, and overarch expression decreased significantly glucose intake.</text>
                    <arg n="0">overarch expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="290">
                    <text>The elevation of the arcA gene caused approximately a 2-fold increase in the expression ptsG, and overarch expression will significantly decreased glucose intake.</text>
                    <arg n="0">overarch expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="291">
                    <text>The elevation of the arcA gene causes a 2-fold increase in the expression ptsG, and glucose intake decreased significantly for exposing excessive arcA will be significantly smaller.</text>
                    <arg n="0">exposing excessive arcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="292">
                    <text>The elevation of the arcA gene causes a 2-fold increase in the expression ptsG, and glucose intake will have been significantly decreased in excessive arc expression.</text>
                    <arg n="0">excessive arc expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="293">
                    <text>The elevation of the arcA gene causes a 2-fold increase in the expression ptsG, and it is thought that over Arca expression significantly decreases glucose intake.</text>
                    <arg n="0">over Arca expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="294">
                    <text>The elevation of the arcA gene causes a 2-fold increase in the expression ptsG, and over Arca expression can significantly decrease glucose intake.</text>
                    <arg n="0">over Arca expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="295">
                    <text>The elevation of the arcA gene causes a 2-fold increase in the expression ptsG, and over Arca expression decreases significantly the glucose intake.</text>
                    <arg n="0">over Arca expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="296">
                    <text>The elevation of the arcA gene causes a 2-fold increase in the expression ptsG, and overarch expression was able to significantly decrease glucose intake.</text>
                    <arg n="0">overarch expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="297">
                    <text>The elevation of the arcA gene causes a 2-fold increase in the expression ptsG, and overarch expression will significantly decrease the glucose intake.</text>
                    <arg n="0">overarch expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="298">
                    <text>The elevation of the arcA gene causes a 2-fold increase in the expression ptsG, and overarch expression would significantly decrease the glucose intake.</text>
                    <arg n="0">overarch expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="299">
                    <text>The elevation of the arcA gene causes an increase of about 2-fold in the expression ptsG, and glucose intake may have been significantly decreased in exposing excessive arcA will be significantly smaller.</text>
                    <arg n="0">exposing excessive arcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="300">
                    <text>The elevation of the arcA gene decrease a 2-fold increase in the expression ptsG, and over ArcA expression shows a significant decrease in glucose intake.</text>
                    <arg n="0">over ArcA expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="301">
                    <text>The elevation of the arcA gene decreased a 2-fold increase in the expression ptsG, and over Arca expression can have a significant decrease in glucose intake.</text>
                    <arg n="0">over Arca expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="302">
                    <text>The elevation of the arcA gene decreased a 2-fold increase in the expression ptsG, and over expression of Arca is thought to have a significant decrease in glucose intake.</text>
                    <arg n="0">over expression of Arca</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="303">
                    <text>The narL breakdown showed that it decreases the nirB promoter nirB induction without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL breakdown</arg>
                    <arg n="1">nirB promoter nirB induction</arg>
                </example>
                <example src="EGRAM" no="304">
                    <text>The narL drive is thought to decrease the nirB promoter nitrite induction without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="305">
                    <text>The narL drive will have decreased the nirB promoter nitrite induction without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="306">
                    <text>The nitrite induction of the nirB promoter could be decreased by the narL drive that was not suppressing nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="307">
                    <text>The nitrite induction of the nirB promoter has been decreased by narL drive which does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="308">
                    <text>The nitrite induction of the nirB promoter has been decreased by narL-disruption which has not been suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL-disruption</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="309">
                    <text>The nitrite induction of the nirB promoter may have been decreased by narL drive which does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="310">
                    <text>The nitrite induction of the nirB promoter was considered a decrease by the withdrawal of the narcotic, which did not suppress the induction of nitrate, decreased that there could be a second nitrate response factor.</text>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="311">
                    <text>The nitrite induction of the nirB promoter was decreased by narcotic removal, which did not suppress nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narcotic removal</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="312">
                    <text>The nitrite induction of the nirB promoter was decreased by narcotic removal, which was not suppressed by nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narcotic removal</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="313">
                    <text>The nitrite induction of the nirB promoter was decreased by the narL drive that did not suppress nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="314">
                    <text>The nitrite induction of the nirB promoter was decreased in the nail blackout, which does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">nail blackout</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="315">
                    <text>The nitrite induction of the nirB promoter will be decreased by narcotic removal, which does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narcotic removal</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="316">
                    <text>The nitrite induction of the nirB promoter will be decreased by the narL drive that does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="317">
                    <text>The nitrite induction of the nirB promoter would be decreased by narcotic removal, which did not suppress nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narcotic removal</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="318">
                    <text>The nitrite induction of the nirB promoter would be decreased by the narL drive that did not suppress nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="319">
                    <text>The production of C51 microcin was considered to be decreasing or absent in rpoS, crp and cyanol mutant cells.</text>
                    <arg n="2">rpoS, crp and cyanol mutant cells</arg>
                </example>
                <example src="EGRAM" no="320">
                    <text>The protein levels secreting crystal cells was considered to be decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin and a phosphorylated form of cytotin S.Syntrophin binds to an alternative pulsus</text>
                    <arg n="1">protein levels secreting crystal cells</arg>
                </example>
                <example src="EGRAM" no="321">
                    <text>The removal of the arcA gene causes a 2-fold increase in the expression of ptsG, and glucose intake is thought to decreased significantly in excessive arc expression will be significant.</text>
                    <arg n="0">excessive arc expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="322">
                    <text>The removal of the arcA gene causes a 2-fold increase in the expression of ptsG, and it is thought that glucose intake is significantly decreased, since excessive arc expression will be significantly decreased.</text>
                    <arg n="0">excessive arc expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="323">
                    <text>The removal of the arcA gene causes a 2-fold increase in the expression of ptsG, and over expression of ArcA is shown to significantly decreased glucose intake.</text>
                    <arg n="0">over expression of ArcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="324">
                    <text>The removal of the arcA gene causes a 2-fold increase in the expression ptsG, and glucose intake can be significantly decreased for excessive arc expression.</text>
                    <arg n="0">excessive arc expression</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="325">
                    <text>The removal of the arcA gene causes a 2-fold increase in the expression ptsG, and glucose intake can be significantly decreased for exposing excessive arcA will be significantly smaller.</text>
                    <arg n="0">exposing excessive arcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="326">
                    <text>The removal of the arcA gene causes a 2-fold increase in the expression ptsG, and glucose intake may have been significantly decreased in exposing excessive arcA will be significantly smaller.</text>
                    <arg n="0">exposing excessive arcA</arg>
                    <arg n="1">glucose intake</arg>
                </example>
                <example src="EGRAM" no="327">
                    <text>The suppression of the arcA gene caused a 2-fold increase in the expression ptsG, and arcA expression has significantly decreased glucose consumption.</text>
                    <arg n="0">arcA expression</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="328">
                    <text>The suppression of the arcA gene caused a 2-fold increase in the expression ptsG, and the glucose consumption has been significantly decreased for the excessive expression of Arca to do so significantly.</text>
                    <arg n="0">the excessive expression of Arca</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="329">
                    <text>The suppression of the arcA gene caused a 2-fold increase in the expression ptsG, and the glucose consumption was significantly decreased for the excessive expression of Arca in a significant manner.</text>
                    <arg n="0">the excessive expression of Arca</arg>
                    <arg n="1">the glucose consumption</arg>
                </example>
                <example src="EGRAM" no="330">
                    <text>Treaty with melatonin is shown to decrease lipid peroxide synthesis, and allows for the recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="0">Treaty with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="331">
                    <text>Treaty with melatonin was able to decrease lipid peroxide synthesis, and allowed the recovery of reduced glutathione and scavenger activity.</text>
                    <arg n="0">Treaty with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="332">
                    <text>clac secretor protein levels can be reduced in NLF smokers, and it is also found that the NLF of smokers contains decreased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">clac secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="333">
                    <text>clac secretor protein levels can be reduced in smokers NLF, and it has also been found that the NLF of smokers contains decreased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">clac secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="334">
                    <text>clac secretor protein levels is capable of decreasing in the NLF of smokers, and it is also found that the NLF of smokers contains decreased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">clac secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="335">
                    <text>claco secretory protein levels is able to decreased the NLF of smokers, and NLF of smokers has also been found to contain an increase in the ratio of a truncated lipocortin-1 variant, three acid forms of alpha (1)-antitrypsin and a phosphorylated form of cytotin S.Syntrophin binds to a dystropine exon sp</text>
                    <arg n="1">claco secretory protein levels</arg>
                </example>
                <example src="EGRAM" no="336">
                    <text>clench cell secretor protein levels is considered to be decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin and a phosphorylated form of cyttin S. Sintropin binds to an alternative pulsed exon of</text>
                    <arg n="1">clench cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="337">
                    <text>cloth cell secretor protein levels is thought to have been decreased in smokers NLF, and it is also found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">cloth cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="338">
                    <text>cloth cell secretor protein levels will be reduced in the NLF of smokers, and it is also found that the NLF of smokers contains decreased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin, and a phosphorylated form of cytotin S.Syntrophin binds to an exon spalmate of dystrophin.</text>
                    <arg n="1">cloth cell secretor protein levels</arg>
                </example>
                <example src="EGRAM" no="339">
                    <text>expressive expression of OmpF pores in multi-resistant mutants (Mar) of Escherichia coli may have been decreased in amara place.</text>
                    <arg n="0">amara place</arg>
                    <arg n="1">expressive expression of OmpF pores</arg>
                    <arg n="2">multi-resistant mutants (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="340">
                    <text>expressive expression of OmpF pores in multi-resistant mutants (Mar) of Escherichia coli was decreased in mar place.</text>
                    <arg n="0">mar place</arg>
                    <arg n="1">expressive expression of OmpF pores</arg>
                    <arg n="2">multi-resistant mutants (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="341">
                    <text>hair peroxide synthesis can be decreased by melatonin treatment, and allows for the recovery of both decreased glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">hair peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="342">
                    <text>hair peroxide synthesis has been shown to be decreased by melatonin treatment, and allows both glutathione reduction and scavenger enzyme to recover.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">hair peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="343">
                    <text>hair peroxide synthesis may have been decreased by melatonin treatment, and is allowed to recover both decreased glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">hair peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="344">
                    <text>hair peroxide synthesis will be decreased by melatonin treatment, and allows for the recovery of both decreased glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">hair peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="345">
                    <text>levels of crystalline cell secretor proteins was decreased in the NLF of smokers, and it was also found that the NLF of smokers contained increased ratios of a truncated variant of lipocortin-1, three acidic alpha forms (1)-antitrypsin and a phosphorylated form of cyttin S.Syntrophin binds to an alternative pulsed exon of</text>
                    <arg n="1">levels of crystalline cell secretor proteins</arg>
                </example>
                <example src="EGRAM" no="346">
                    <text>lipid peroxide synthesis can be decreased by Tractally with melatonin, and allows for the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="347">
                    <text>lipid peroxide synthesis could be decreased by Tractally with melatonin, and allowed for the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="348">
                    <text>lipid peroxide synthesis has been decreased by Tractally with melatonin, and has allowed the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="349">
                    <text>lipid peroxide synthesis has decreased by Tractally with melatonin, and allows for the recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="350">
                    <text>lipid peroxide synthesis is decreased by Tractally with melatonin, and allows for the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="351">
                    <text>lipid peroxide synthesis is thought to be decreased by Tractally with melatonin, and allows for the recovery of both decreased glutathione and scavenger enzymatic activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="352">
                    <text>lipid peroxide synthesis may have been decreased by Tractally with melatonin, and has allowed the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="353">
                    <text>lipid peroxide synthesis may have been decreased by Tractally with melatonin, and has allowed the recovery of both decreased glutathione and scavenger enzymatic activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="354">
                    <text>lipid peroxide synthesis was able to be decreased by Tractally with melatonin, and allowed for the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="355">
                    <text>lipid peroxide synthesis was able to be decreased by melatonin treatment, and allowed for the recovery of both decreased glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="356">
                    <text>lipid peroxide synthesis was considered to be decreased by melatonin treatment, and allowed the recovery of both reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="357">
                    <text>lipid peroxide synthesis was decreased by Tractally with melatonin, and allowed for the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="358">
                    <text>lipid peroxide synthesis was decreased by melatonin treatment, and allowed the recovery of both reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="359">
                    <text>lipid peroxide synthesis was decreased to Tractally with melatonin, and allowed both decreased glutathione and scaveners activity to recover.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="360">
                    <text>lipid peroxide synthesis was thought to be decreased by Tractally with melatonin, and allowed for the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="361">
                    <text>lipid peroxide synthesis will be decreased by Tractally with melatonin, and allows for the recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="362">
                    <text>lipid peroxide synthesis would be decreased by Tractally with melatonin, and would allow a recovery of both decreased glutathione and scavenger activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="363">
                    <text>lipody peroxide synthesis can be decreased by melatonin treatment, and allows the recovery of both reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipody peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="364">
                    <text>lipody peroxide synthesis has been shown to be decreased by melatonin treatment, and allowed both decreased glutathione and scavenger activity to recover.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipody peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="365">
                    <text>lipody peroxide synthesis has been shown to be decreased by melatonin treatment, and allows both reduced glutathione and scavenger enzyme to recover.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipody peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="366">
                    <text>lipody peroxide synthesis is able to be decreased by Tractally with melatonin, and allows the recovery of both decreased glutathione and scaveners activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipody peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="367">
                    <text>lipody peroxide synthesis is able to be decreased by melatonin treatment, and allows both reduced glutathione and scavenger enzyme to be recovered.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipody peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="368">
                    <text>lipody peroxide synthesis is decreased by Tractally with melatonin, and allows the recovery of both decreased glutathione and scaveners activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipody peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="369">
                    <text>lipody peroxide synthesis is thought to be decreased by Tractally with melatonin, and allows both decreased glutathione and scavenger enzyme to recover.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipody peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="370">
                    <text>lipody peroxide synthesis may have been decreased to Tractally with melatonin, and allowed the recovery of both decreased glutathione and scavenger enzyme.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipody peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="371">
                    <text>lipody peroxide synthesis would be decreased by Tractally with melatonin, and would allow the recovery of both decreased glutathione and scaveners activity.</text>
                    <arg n="0">Tractally with melatonin</arg>
                    <arg n="1">lipody peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="372">
                    <text>loco marA decreased porin OmpF expression in multants of Escherichia coli resistant to multiple antibiotics (Mar).</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">porin OmpF expression</arg>
                    <arg n="2">multants of Escherichia coli resistant to multiple antibiotics (Mar)</arg>
                </example>
                <example src="EGRAM" no="373">
                    <text>loco marA decreased the Purina OmpF expression in Many of Scherichia coli resistant to multiple antibiotics (Mar).</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">Purina OmpF expression</arg>
                    <arg n="2">Many of Scherichia coli resistant to multiple antibiotics (Mar)</arg>
                </example>
                <example src="EGRAM" no="374">
                    <text>loco marA decreased the or OmpF porin expression in A2 mutants (multi-antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">or OmpF porin expression</arg>
                </example>
                <example src="EGRAM" no="375">
                    <text>loco marA decreases expression of porin OmpF in multants of Escherichia coli resistant to multiple antibiotics (Mar).</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">expression of porin OmpF</arg>
                    <arg n="2">multants of Escherichia coli resistant to multiple antibiotics (Mar)</arg>
                </example>
                <example src="EGRAM" no="376">
                    <text>loco marA has been shown to decrease or OmpF porin expression in mutants of Escherichia coli resisting with multiple antibiotics (Mar).</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">or OmpF porin expression</arg>
                    <arg n="2">resisting with multiple antibiotics (Mar)</arg>
                </example>
                <example src="EGRAM" no="377">
                    <text>loco marA has the ability to decrease the Purina OmpF expression to Many of Scherichia coli resistant to multiple antibiotics (Mar).</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">Purina OmpF expression</arg>
                    <arg n="2">Many of Scherichia coli resistant to multiple antibiotics (Mar)</arg>
                </example>
                <example src="EGRAM" no="378">
                    <text>loco marA is able to decrease expression of porin OmpF in A2 mutants (resistant to multiple antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">expression of porin OmpF</arg>
                </example>
                <example src="EGRAM" no="379">
                    <text>loco marA is able to decrease the OmpF porin expression in A2 mutants (multi-antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">OmpF porin expression</arg>
                </example>
                <example src="EGRAM" no="380">
                    <text>loco marA may decrease expression of porin OmpF in A2 mutants (resistant to multiple antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">expression of porin OmpF</arg>
                </example>
                <example src="EGRAM" no="381">
                    <text>loco marA may decrease expression of porin OmpF in mutants of Escherichia coli resistant to multiple antibiotics (Mar).</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">expression of porin OmpF</arg>
                    <arg n="2">resistant to multiple antibiotics (Mar)</arg>
                </example>
                <example src="EGRAM" no="382">
                    <text>loco marA may have decreased perhaps OmpF porin expression in A2 mutants (multi-antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">perhaps OmpF porin expression</arg>
                </example>
                <example src="EGRAM" no="383">
                    <text>loco marA may have decreased porin expression OmpF in A2 mutants (resistant to multiple antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">porin expression OmpF</arg>
                </example>
                <example src="EGRAM" no="384">
                    <text>loco marA was able to decrease the or OmpF porin expression in A2 mutants (multi-antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">or OmpF porin expression</arg>
                </example>
                <example src="EGRAM" no="385">
                    <text>loco marA was shown to decrease the opmpF porin expression in A2 mutants (multi-antibiotics (Mar) of Escherichia coli.</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">opmpF porin expression</arg>
                </example>
                <example src="EGRAM" no="386">
                    <text>loco marA will decrease expression of porin OmpF in mutants of Escherichia coli resistant to multiple antibiotics (Mar).</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">expression of porin OmpF</arg>
                    <arg n="2">resistant to multiple antibiotics (Mar)</arg>
                </example>
                <example src="EGRAM" no="387">
                    <text>loco marA will decrease the OmpF porin expression in mutants of Escherichia coli multi-antibiotic resistant (Mar).</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multi-antibiotic resistant (Mar)</arg>
                </example>
                <example src="EGRAM" no="388">
                    <text>loco marA would decrease the OmpF porin expression in mutants of Escherichia coli multi-antibiotic resistant (Mar).</text>
                    <arg n="0">loco marA</arg>
                    <arg n="1">OmpF porin expression</arg>
                    <arg n="2">multi-antibiotic resistant (Mar)</arg>
                </example>
                <example src="EGRAM" no="389">
                    <text>locus marA is believed to decrease porin expression OmpF in A2 (multi-resistant mutants (Mar) of Escherichia coli.</text>
                    <arg n="0">locus marA</arg>
                    <arg n="1">porin expression OmpF</arg>
                </example>
                <example src="EGRAM" no="390">
                    <text>melatonin treatment can decrease lipodyl peroxide synthesis, and allows for the recovery of both reduced glutathione and scavenger enzymes.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipodyl peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="391">
                    <text>melatonin treatment can decrease the synthesis of lipodyl peroxide, and allow for the recovery of reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                </example>
                <example src="EGRAM" no="392">
                    <text>melatonin treatment decreased the synthesis of lipodyl peroxide and allowed the recovery of reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                </example>
                <example src="EGRAM" no="393">
                    <text>melatonin treatment decreases the lipodyl peroxide synthesis and allows the recovery of reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipodyl peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="394">
                    <text>melatonin treatment has been shown to decrease lipodyl peroxide synthesis, and allows for the recovery of both reduced glutathione and scavenger enzyme.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipodyl peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="395">
                    <text>melatonin treatment is thought to decrease lipodyl peroxide synthesis and allows both reduced glutathione and scavenger activity to recover.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipodyl peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="396">
                    <text>melatonin treatment may decrease the synthesis of lipid peroxide, and allows a reduced recovery of glutathione and scaveners activity.</text>
                    <arg n="0">melatonin treatment</arg>
                </example>
                <example src="EGRAM" no="397">
                    <text>melatonin treatment would decrease lipodyl peroxide synthesis, and would allow for both reduced glutathione and scaveners activity to recover.</text>
                    <arg n="0">melatonin treatment</arg>
                    <arg n="1">lipodyl peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="398">
                    <text>narL discontinuation is able to decrease nirB promoter nitric induction, while not suppressing nitrate induction, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">narL discontinuation</arg>
                    <arg n="1">nirB promoter nitric induction</arg>
                </example>
                <example src="EGRAM" no="399">
                    <text>narcophagus aborted may have decreased nitric nirB promoter induction, although it does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narcophagus aborted</arg>
                    <arg n="1">nitric nirB promoter induction</arg>
                </example>
                <example src="EGRAM" no="400">
                    <text>narcophagus interruption could decrease nitric induction nitric nirB promoter induction while not suppressing nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narcophagus interruption</arg>
                    <arg n="1">nitric nirB promoter induction</arg>
                </example>
                <example src="EGRAM" no="401">
                    <text>narcophagus interruption may decrease the nitric induction of nitric induction promoter of nirB, while it does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narcophagus interruption</arg>
                    <arg n="1">nitric induction promoter of nirB</arg>
                </example>
                <example src="EGRAM" no="402">
                    <text>narcophagus interruption would decrease nirB-promoting nirB-induction, while it would not suppress nitrate induction, suggesting that there might be a second nitrate response factor.</text>
                    <arg n="0">narcophagus interruption</arg>
                </example>
                <example src="EGRAM" no="403">
                    <text>natron activation may decrease nitrite induction nitrogen nitrite induction of nitrite promoters without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">natron activation</arg>
                    <arg n="1">nitrogen nitrite induction of nitrite promoters</arg>
                </example>
                <example src="EGRAM" no="404">
                    <text>natron activation will decreased nitrite induction of nickel nitrite promoters without suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">natron activation</arg>
                    <arg n="1">nitrite induction of nickel nitrite promoters</arg>
                </example>
                <example src="EGRAM" no="405">
                    <text>natron activation would decrease nitrite induction nitrogen nitrite induction of nitrite promoters without suppressing nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">natron activation</arg>
                    <arg n="1">nitrogen nitrite induction of nitrite promoters</arg>
                </example>
                <example src="EGRAM" no="406">
                    <text>nirB promoter nitrite induction is able to be decreased by narL withdrawal, which is not suppressing nitrate induction, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">narL withdrawal</arg>
                    <arg n="1">nirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="407">
                    <text>nirB promoter nitrite induction may have been decreased by narthida withdrawal, which is not suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narthida withdrawal</arg>
                    <arg n="1">nirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="408">
                    <text>nitrite induction from the nirB promoter can be decreased by narL drive that does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="409">
                    <text>nitrite induction from the nirB promoter can be decreased by narL drive which does not eliminate nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="410">
                    <text>nitrite induction from the nirB promoter can be decreased by narL drive which does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="411">
                    <text>nitrite induction from the nirB promoter can be decreased by narcotic removal, which is not suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narcotic removal</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="412">
                    <text>nitrite induction from the nirB promoter can be decreased by narcotic withdrawal, which does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narcotic withdrawal</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="413">
                    <text>nitrite induction from the nirB promoter is decreased by narL-disruption that does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL-disruption</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="414">
                    <text>nitrite induction from the nirB promoter is decreased by narcotic removal, which does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narcotic removal</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="415">
                    <text>nitrite induction from the nirB promoter is shown to be decreased by narL drive that does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="416">
                    <text>nitrite induction from the nirB promoter may have been decreased by narL drive that is not suppressing nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="417">
                    <text>nitrite induction from the nirB promoter was able to be decreased by narL drive that did not eliminate nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="418">
                    <text>nitrite induction from the nirB promoter was shown to decreased for narL drive that it did not suppress nitrate induction, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction from the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="419">
                    <text>nitrite induction of the nirB promoter is capable of being decreased by narL drive that does not suppress nitrate induction, suggesting that there may be a second nitrate response factor.</text>
                    <arg n="0">narL drive</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="420">
                    <text>perhaps NarL was able to decrease nirB-induced nirB-promoting nirB-induction while not suppressing nitrate-inducing, suggesting that there could be a second nitrate response factor.</text>
                    <arg n="0">perhaps NarL</arg>
                </example>
                <example src="EGRAM" no="421">
                    <text>pore expression in multi-resistant mutants (Mar) of Escherichia coli has decreased to MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">pore expression</arg>
                    <arg n="2">multi-resistant mutants (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="422">
                    <text>pore expression in mutants resistant to antibiotics (Mar) of Escherichia coli may have been decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">pore expression</arg>
                    <arg n="2">mutants resistant to antibiotics (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="423">
                    <text>pore expression in mutants resistant to antibiotics (Mar) of Escherichia coli would be decreased by MarA locus.</text>
                    <arg n="0">MarA locus</arg>
                    <arg n="1">pore expression</arg>
                    <arg n="2">mutants resistant to antibiotics (Mar) of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="424">
                    <text>porin OmpF expression in multi-antibiotic resistant Escherichia coli (Mar) mutants is able to be decreased by A0 (marA locus) (multi-antibiotic resistant Escherichia coli (Mar) mutants is able to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">porin OmpF expression</arg>
                    <arg n="2">multi-antibiotic resistant Escherichia coli (Mar) mutants is able to be decreased by A0 (marA locus)</arg>
                </example>
                <example src="EGRAM" no="425">
                    <text>porin OmpF expression in multi-antibiotic resistant Escherichia coli (Mar) mutants is considered to be decreased by A0 (marA locus) (multi-antibiotic resistant Escherichia coli (Mar) mutants is considered to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">porin OmpF expression</arg>
                    <arg n="2">multi-antibiotic resistant Escherichia coli (Mar) mutants is considered to be decreased by A0 (marA locus)</arg>
                </example>
                <example src="EGRAM" no="426">
                    <text>porin OmpF expression in multi-antibiotic resistant Escherichia coli (Mar) mutants is decreased in A0 (marA locus) (multi-antibiotic resistant Escherichia coli (Mar) mutants is decreased in marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">porin OmpF expression</arg>
                    <arg n="2">multi-antibiotic resistant Escherichia coli (Mar) mutants is decreased in A0 (marA locus)</arg>
                </example>
                <example src="EGRAM" no="427">
                    <text>porin OmpF expression in multi-antibiotic resistant Escherichia coli (Mar) mutants may be decreased by A0 (marA locus) (multi-antibiotic resistant Escherichia coli (Mar) mutants may be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">porin OmpF expression</arg>
                    <arg n="2">multi-antibiotic resistant Escherichia coli (Mar) mutants may be decreased by A0 (marA locus)</arg>
                </example>
                <example src="EGRAM" no="428">
                    <text>porin OmpF expression in multi-antibiotic resistant Escherichia coli (Mar) mutants may be decreased in A0 (marA locus) (multi-antibiotic resistant Escherichia coli (Mar) mutants may be decreased in marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">porin OmpF expression</arg>
                    <arg n="2">multi-antibiotic resistant Escherichia coli (Mar) mutants may be decreased in A0 (marA locus)</arg>
                </example>
                <example src="EGRAM" no="429">
                    <text>porin OmpF expression in multi-antibiotic resistant Escherichia coli (Mar) mutants will be decreased in A0 (marA locus) (multi-antibiotic resistant Escherichia coli (Mar) mutants will be decreased in marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">porin OmpF expression</arg>
                    <arg n="2">multi-antibiotic resistant Escherichia coli (Mar) mutants will be decreased in A0 (marA locus)</arg>
                </example>
                <example src="EGRAM" no="430">
                    <text>porin OmpF expression in multi-antibiotic-resistant Escherichia coli (Mar) mutants was able to be decreased in A0 (marA locus) (multi-antibiotic-resistant Escherichia coli (Mar) mutants was able to be decreased in marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">porin OmpF expression</arg>
                    <arg n="2">multi-antibiotic-resistant Escherichia coli (Mar) mutants was able to be decreased in A0 (marA locus)</arg>
                </example>
                <example src="EGRAM" no="431">
                    <text>porin expression OmpF in Multi-antibiotic-resistant Escherichia coli (Mar) mutants was decreased in A0 (marA locus) (Multi-antibiotic-resistant Escherichia coli (Mar) mutants was decreased in marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">porin expression OmpF</arg>
                    <arg n="2">Multi-antibiotic-resistant Escherichia coli (Mar) mutants was decreased in A0 (marA locus)</arg>
                </example>
                <example src="EGRAM" no="432">
                    <text>production of C51 microcins may decrease or be absent in the A2 mutant cells (rpoS, crp and cya).</text>
                    <arg n="1">production of C51 microcins</arg>
                </example>
                <example src="EGRAM" no="433">
                    <text>production of C51 microcins will decrease or be absent in the A2 mutant cells (rpoS, crp and cya).</text>
                    <arg n="1">production of C51 microcins</arg>
                </example>
                <example src="EGRAM" no="434">
                    <text>production of microcines C51 is able to decrease or be absent in mutant cells rpoS, crp and cya.</text>
                    <arg n="1">production of microcines C51</arg>
                    <arg n="2">rpoS, crp and cya</arg>
                </example>
                <example src="EGRAM" no="435">
                    <text>production of microcins C51 decreased or was absent in the A2 mutant cells (rpoS, crp and cya).</text>
                    <arg n="1">production of microcins C51</arg>
                </example>
                <example src="EGRAM" no="436">
                    <text>production of microcins C51 decreases or decreases absent in the mutant cells rpoS, crp and cya.</text>
                    <arg n="1">production of microcins C51</arg>
                    <arg n="2">rpoS, crp and cya</arg>
                </example>
                <example src="EGRAM" no="437">
                    <text>production of microcins C51 had the ability to decrease or be absent in the A2 mutant cells (rpoS, crp and cya).</text>
                    <arg n="1">production of microcins C51</arg>
                </example>
                <example src="EGRAM" no="438">
                    <text>production of microcins C51 has the ability to decrease or be absent in the A2 mutant cells (rpoS, crp and cya).</text>
                    <arg n="1">production of microcins C51</arg>
                </example>
                <example src="EGRAM" no="439">
                    <text>production of microcins C51 is considered to be decreasing or absent in the A2 mutant cells (rpoS, crp and cya).</text>
                    <arg n="1">production of microcins C51</arg>
                </example>
                <example src="EGRAM" no="440">
                    <text>production of microcins C51 was able to decrease or be absent in the A2 mutant cells (rpoS, crp and cya).</text>
                    <arg n="1">production of microcins C51</arg>
                </example>
                <example src="EGRAM" no="441">
                    <text>production of microcins C51 would decrease or be absent in the mutant cells rpoS, crp and cya.</text>
                    <arg n="1">production of microcins C51</arg>
                    <arg n="2">rpoS, crp and cya</arg>
                </example>
                <example src="EGRAM" no="442">
                    <text>rupture of narL will decrease nirB promoter nitrite induction, while not suppressing nitrate induction, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">rupture of narL</arg>
                    <arg n="1">nirB promoter nitrite induction</arg>
                </example>
                <example src="EGRAM" no="443">
                    <text>the production of C51 microcin could decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="444">
                    <text>the production of C51 microcin decreases or decreases absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="445">
                    <text>the production of C51 microcin had the ability to decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="446">
                    <text>the production of C51 microcin has decreased or been absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="447">
                    <text>the production of C51 microcin has the ability to decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="448">
                    <text>the production of C51 microcin is able to decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="449">
                    <text>the production of C51 microcin is shown to decrease or is absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="450">
                    <text>the production of C51 microcin may decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="451">
                    <text>the production of C51 microcin was able to decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="452">
                    <text>the production of C51 microcin was shown to decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="453">
                    <text>the production of C51 microcin was thought to decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="454">
                    <text>the production of C51 microcin will decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="455">
                    <text>the production of C51 microcin would decrease or be absent in rpoS, crp, and cya mutant cells.</text>
                    <arg n="1">the production of C51 microcin</arg>
                    <arg n="2">rpoS, crp, and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="456">
                    <text>treatment with melatonin can decrease lipid peroxide synthesis, and allows for reduced glutathione recovery and scavenger activity.</text>
                    <arg n="0">treatment with melatonin</arg>
                </example>
                <example src="EGRAM" no="457">
                    <text>treatment with melatonin can decrease lipid peroxide synthesis, and allows for the recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="0">treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="458">
                    <text>treatment with melatonin could decrease lipid peroxide synthesis, and allowed a recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="0">treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="459">
                    <text>treatment with melatonin decreases lipid peroxide synthesis, and allows for the recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="0">treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="460">
                    <text>treatment with melatonin is thought to decrease lipid peroxide synthesis, and allow for the recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="0">treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="461">
                    <text>treatment with melatonin was thought to decrease lipid peroxide synthesis, and allowed for a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="462">
                    <text>treatment with melatonin will decrease lipid peroxide synthesis, and allow for the recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="0">treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="463">
                    <text>treatment with melatonin would decrease lipid peroxide synthesis, and allow for a recovery of both reduced glutathione and scavenger activity.</text>
                    <arg n="0">treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
